Pharma Wants More Clarity On Use Of Auxiliary Products In EU Trials
Executive Summary
Pharmaceutical companies say that more clarification is needed on a European Commission proposal that offers a revised definition for investigational medicinal products and deals with the use of auxiliary medicinal products in clinical trials.
You may also be interested in...
Commission Consults On New Risk-Proportionate Approaches Under EU Clinical Trials Regulation
The European Commission is inviting stakeholder feedback on recommendations to help implement several key aspects of the new EU Clinical Trials Regulation, including how to apply a risk proportionate approach for the design and conduct of trials, and how to present a summary of clinical trial results to laypersons1.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.